Andrew Parker

Andrew has more than twenty years of experience from senior leadership and managerial positions in international pharmaceutical, biotech and start-up companies, including several years with Shire Pharmaceuticals, Opsona Therapeutics, and AstraZeneca as well as VC experience as General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2. Prior to joining Step Pharma he was CSO at Zealand Pharm in Denmark.

Andrew holds a Ph.D. from the National Institute for Medical Research at Mill Hill, London, conducted post-doctoral research at Johns Hopkins Medical School, Baltimore, USA, and also has an MBA from the University of Warwick Business School, UK.